GlassScriptPhysician profile
Mohitmeet Singh
NPI 1083929863
$2,261.41
in general payments reported to CMS, 2019-2025
18 companies · $366 in 2025
The $366 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $295 · 2020: $187 · 2021: $356 · 2022: $557 · 2023: $212 · 2024: $289 · 2025: $366.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $867.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $866.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $668.66 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $226.08 | 2019-2025 | Eliquis |
| Pfizer INC. | $190.07 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $178.09 | 2019-2023 | |
| Abbott Laboratories | $176.47 | 2022 | |
| Merck Sharp & Dohme LLC | $132.98 | 2024-2025 | Zerbaxa, Dificid, Recarbrio |
| Urovant Sciences INC | $124.59 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $121.32 | 2025 | |
| Mallinckrodt Hospital Products INC. | $118.39 | 2021 | |
| Mylan Specialty L.P. | $114.78 | 2023 | Yupelri |
| Smith+Nephew, INC. | $38.23 | 2025 | Collagenase Santyl |
| Alkermes, INC. | $28.68 | 2025 | Aristada, Lybalvi |
| Amneal Pharmaceuticals LLC | $26.85 | 2025 | Crexont |
| Teva Pharmaceuticals USA, INC. | $25.67 | 2025 | Austedo Xr |
| Abbvie INC. | $24.90 | 2025 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $24.80 | 2024 | Briviact |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $22.68 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.17 | 2023 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohitmeet Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.